PharmAbcine Inc.
Clinical-stage biotech developing human monoclonal antibodies for various diseases.
208340 | KO
Overview
Corporate Details
- ISIN(s):
- KR7208340000
- LEI:
- Country:
- South Korea
- Address:
- 대전광역시 유성구 유성대로1689번길 70 KT대덕2연구센터 연구2동 2층, 대전광역시
- Website:
- http://pharmabcine.com/
- Sector:
- Manufacturing
Description
PharmAbcine Inc. is a clinical-stage biotechnology company specializing in the development of fully human therapeutic monoclonal antibodies (mAbs). The company focuses on creating innovative treatments for diseases with high unmet medical needs, primarily in oncology, neovascular eye diseases, and other inflammatory and vascular disorders. Utilizing its proprietary human antibody library and discovery technologies, PharmAbcine advances a pipeline of next-generation IgG-based therapeutics. The company's mission is to contribute to human health by providing novel antibody-based drugs to patients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-03-15 00:00 |
사업보고서 (2022.12)
|
Korean | HTML • 1.5 MB | ||
| 2023-02-28 00:00 |
주주총회소집공고
|
Korean | HTML • 158.0 KB | ||
| 2023-02-28 00:00 |
의결권대리행사권유참고서류
|
Korean | HTML • 157.8 KB | ||
| 2023-02-24 00:00 |
투자판단관련주요경영사항(재발성 교모세포종 환자를 대상으로 Pembrolizumab과 TTAC-0001 병용요법의 안전성 및 내약성을 평가하기 …
|
Korean | HTML • 13.1 KB | ||
| 2023-02-24 00:00 |
투자판단관련주요경영사항(전이성 삼중음성 유방암 환자를 대상으로 Pembrolizumab과 TTAC-0001 병용요법의 안전성 및 내약성을 평가…
|
Korean | HTML • 13.0 KB | ||
| 2023-02-21 00:00 |
주주총회소집결의
|
Korean | HTML • 13.6 KB | ||
| 2023-01-30 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | HTML • 12.0 KB | ||
| 2022-12-20 00:00 |
투자판단관련주요경영사항(신생혈관성 연령관련 황반변성 환자를 대상으로 PMC-403 단회 및 반복 투여 용량 증량의 안전성 및 내약성을 평가하기…
|
Korean | HTML • 13.3 KB | ||
| 2022-12-15 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | HTML • 4.1 KB | ||
| 2022-11-14 00:00 |
[기재정정]분기보고서 (2022.09)
|
Korean | DOC • 1.3 MB | ||
| 2022-11-11 00:00 |
분기보고서 (2022.09)
|
Korean | DOC • 1.3 MB | ||
| 2022-08-16 00:00 |
반기보고서 (2022.06)
|
Korean | DOC • 1.2 MB | ||
| 2022-07-15 00:00 |
전환가액의조정
|
Korean | DOC • 10.2 KB | ||
| 2022-07-15 00:00 |
투자판단관련주요경영사항(2상 임상시험 조기 종료)
|
Korean | DOC • 10.5 KB | ||
| 2022-05-16 00:00 |
분기보고서 (2022.03)
|
Korean | DOC • 1.2 MB |
Automate Your Workflow. Get a real-time feed of all PharmAbcine Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for PharmAbcine Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for PharmAbcine Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
